Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.